CDKN2A and astrocytoma (excluding glioblastoma): On univariate analysis, IDH1/2-mutant astrocytoma patients with CDKN2A/B hemizygous loss exhibited significantly shorter survival than their intact CDKN2A/B counterparts within each grade (Figure 1C).